Physician profile
Sandra Pullen
NPI 1053895706
$5,098.93
in general payments reported to CMS, 2019-2025
27 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $978 · 2022: $946 · 2023: $1,044 · 2024: $1,047 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,465.61 | 2021-2025 | |
| Janssen Biotech, INC. | $567.46 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $555.32 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $392.06 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $341.34 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $310.24 | 2022-2025 | |
| Gilead Sciences, INC. | $228.18 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $155.16 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $122.87 | 2021 | |
| Merck Sharp & Dohme LLC | $120.29 | 2021-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $111.27 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $98.80 | 2024-2025 | Resmetirom, Rezdiffra |
| Ethicon US, LLC | $91.31 | 2024 | Linx Reflux Management System |
| Janssen Scientific Affairs, LLC | $89.45 | 2021 | |
| Pfizer INC. | $78.25 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $70.98 | 2021-2024 | Linzess |
| Enterra Medical, INC. | $51.77 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $38.75 | 2024-2025 | Iqirvo |
| Celgene Corporation | $30.45 | 2021-2022 | |
| Braintree Laboratories, INC. | $29.85 | 2022-2023 | Sutab |
| Redhill Biopharma INC. | $27.82 | 2021 | |
| Fresenius Kabi USA, LLC | $25.71 | 2023 | Idacio |
| Novo Nordisk INC | $23.96 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $21.70 | 2025 | Voquezna |
| Boston Scientific Corporation | $20.26 | 2023 | Watchman Flx |
| Medtronic, INC. | $15.23 | 2022 | |
| Lilly USA, LLC | $14.84 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Pullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.